Rockwell Medical, Inc. (RMTI)
USD 1.05
(-1.42%)
USD 1.05
(-1.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 30.88 Million USD | -5.06% |
| 2022 | 32.52 Million USD | -29.34% |
| 2021 | 46.03 Million USD | 5.65% |
| 2020 | 43.57 Million USD | 81.6% |
| 2019 | 23.99 Million USD | -5.08% |
| 2018 | 25.28 Million USD | -2.26% |
| 2017 | 25.86 Million USD | -14.34% |
| 2016 | 30.19 Million USD | 18.41% |
| 2015 | 25.5 Million USD | -12.95% |
| 2014 | 29.29 Million USD | -18.09% |
| 2013 | 35.76 Million USD | 32.53% |
| 2012 | 26.98 Million USD | 97.06% |
| 2011 | 13.69 Million USD | 113.01% |
| 2010 | 6.42 Million USD | 15.71% |
| 2009 | 5.55 Million USD | -22.17% |
| 2008 | 7.13 Million USD | 47.44% |
| 2007 | 4.84 Million USD | 1.33% |
| 2006 | 4.77 Million USD | -11.76% |
| 2005 | 5.41 Million USD | 26.59% |
| 2004 | 4.27 Million USD | 10.47% |
| 2003 | 3.87 Million USD | 13.63% |
| 2002 | 3.4 Million USD | -1.54% |
| 2001 | 3.46 Million USD | 190.71% |
| 2000 | 1.19 Million USD | 32.3% |
| 1999 | 900 Thousand USD | 28.57% |
| 1998 | 700 Thousand USD | -58.82% |
| 1997 | 1.7 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 30.08 Million USD | -2.6% |
| 2024 Q2 | 29.53 Million USD | -1.83% |
| 2023 Q3 | 31.08 Million USD | 9.05% |
| 2023 FY | 30.88 Million USD | -5.06% |
| 2023 Q2 | 28.5 Million USD | 2.07% |
| 2023 Q1 | 27.93 Million USD | -14.14% |
| 2023 Q4 | 30.88 Million USD | -0.66% |
| 2022 FY | 32.52 Million USD | -29.34% |
| 2022 Q3 | 38.05 Million USD | -2.36% |
| 2022 Q1 | 42.24 Million USD | -8.25% |
| 2022 Q2 | 38.97 Million USD | -7.75% |
| 2022 Q4 | 32.52 Million USD | -14.51% |
| 2021 Q1 | 43.27 Million USD | -0.7% |
| 2021 FY | 46.03 Million USD | 5.65% |
| 2021 Q2 | 45.48 Million USD | 5.11% |
| 2021 Q4 | 46.03 Million USD | -3.29% |
| 2021 Q3 | 47.6 Million USD | 4.67% |
| 2020 Q4 | 43.57 Million USD | 0.97% |
| 2020 Q1 | 45.05 Million USD | 87.74% |
| 2020 Q2 | 42.37 Million USD | -5.95% |
| 2020 Q3 | 43.16 Million USD | 1.86% |
| 2020 FY | 43.57 Million USD | 81.6% |
| 2019 FY | 23.99 Million USD | -5.08% |
| 2019 Q3 | 24.38 Million USD | -11.28% |
| 2019 Q2 | 27.48 Million USD | -3.85% |
| 2019 Q4 | 23.99 Million USD | -1.59% |
| 2019 Q1 | 28.58 Million USD | 13.07% |
| 2018 Q4 | 25.28 Million USD | -0.53% |
| 2018 Q1 | 24.58 Million USD | -4.94% |
| 2018 Q2 | 24.52 Million USD | -0.25% |
| 2018 Q3 | 25.41 Million USD | 3.61% |
| 2018 FY | 25.28 Million USD | -2.26% |
| 2017 Q4 | 25.86 Million USD | 3.4% |
| 2017 Q2 | 25.62 Million USD | -14.14% |
| 2017 FY | 25.86 Million USD | -14.34% |
| 2017 Q1 | 29.85 Million USD | -1.14% |
| 2017 Q3 | 25.01 Million USD | -2.39% |
| 2016 Q2 | 29.51 Million USD | 2.15% |
| 2016 Q4 | 30.19 Million USD | 11.44% |
| 2016 FY | 30.19 Million USD | 18.41% |
| 2016 Q3 | 27.09 Million USD | -8.18% |
| 2016 Q1 | 28.89 Million USD | 13.29% |
| 2015 Q4 | 25.5 Million USD | -3.72% |
| 2015 Q1 | 29.33 Million USD | 0.14% |
| 2015 FY | 25.5 Million USD | -12.95% |
| 2015 Q2 | 25.53 Million USD | -12.95% |
| 2015 Q3 | 26.48 Million USD | 3.71% |
| 2014 Q1 | 30.32 Million USD | -15.23% |
| 2014 Q2 | 29.79 Million USD | -1.73% |
| 2014 Q3 | 29.33 Million USD | -1.56% |
| 2014 FY | 29.29 Million USD | -18.09% |
| 2014 Q4 | 29.29 Million USD | -0.12% |
| 2013 Q1 | 28.47 Million USD | 5.51% |
| 2013 Q4 | 35.76 Million USD | -4.62% |
| 2013 Q3 | 37.5 Million USD | 1.93% |
| 2013 FY | 35.76 Million USD | 32.53% |
| 2013 Q2 | 36.78 Million USD | 29.2% |
| 2012 Q1 | 13.83 Million USD | 1.04% |
| 2012 Q4 | 26.98 Million USD | 17.08% |
| 2012 Q3 | 23.04 Million USD | 32.32% |
| 2012 Q2 | 17.41 Million USD | 25.89% |
| 2012 FY | 26.98 Million USD | 97.06% |
| 2011 FY | 13.69 Million USD | 113.01% |
| 2011 Q4 | 13.69 Million USD | 42.24% |
| 2011 Q3 | 9.62 Million USD | 50.98% |
| 2011 Q2 | 6.37 Million USD | 11.26% |
| 2011 Q1 | 5.73 Million USD | -10.85% |
| 2010 FY | 6.42 Million USD | 15.71% |
| 2010 Q2 | 5.94 Million USD | 5.26% |
| 2010 Q1 | 5.64 Million USD | 1.57% |
| 2010 Q3 | 4.88 Million USD | -17.83% |
| 2010 Q4 | 6.42 Million USD | 31.7% |
| 2009 Q3 | 7.04 Million USD | 10.53% |
| 2009 Q1 | 5.45 Million USD | -23.63% |
| 2009 Q2 | 6.37 Million USD | 16.86% |
| 2009 Q4 | 5.55 Million USD | -21.1% |
| 2009 FY | 5.55 Million USD | -22.17% |
| 2008 FY | 7.13 Million USD | 47.44% |
| 2008 Q1 | 4.98 Million USD | 2.99% |
| 2008 Q3 | 6.8 Million USD | 30.63% |
| 2008 Q4 | 7.13 Million USD | 4.89% |
| 2008 Q2 | 5.21 Million USD | 4.49% |
| 2007 Q3 | 6.14 Million USD | 4.24% |
| 2007 FY | 4.84 Million USD | 1.33% |
| 2007 Q1 | 5.2 Million USD | 8.93% |
| 2007 Q2 | 5.89 Million USD | 13.21% |
| 2007 Q4 | 4.84 Million USD | -21.18% |
| 2006 Q3 | 4.15 Million USD | 32.06% |
| 2006 Q4 | 4.77 Million USD | 14.88% |
| 2006 Q1 | 3.27 Million USD | -39.59% |
| 2006 Q2 | 3.14 Million USD | -3.72% |
| 2006 FY | 4.77 Million USD | -11.76% |
| 2005 Q3 | 5.39 Million USD | -8.73% |
| 2005 Q2 | 5.91 Million USD | -0.6% |
| 2005 FY | 5.41 Million USD | 26.59% |
| 2005 Q1 | 5.94 Million USD | 39.07% |
| 2005 Q4 | 5.41 Million USD | 0.34% |
| 2004 Q4 | 4.27 Million USD | 8.22% |
| 2004 Q1 | 4.5 Million USD | 16.24% |
| 2004 Q2 | 4.14 Million USD | -7.93% |
| 2004 Q3 | 3.95 Million USD | -4.62% |
| 2004 FY | 4.27 Million USD | 10.47% |
| 2003 FY | 3.87 Million USD | 13.63% |
| 2003 Q1 | 3.58 Million USD | 5.26% |
| 2003 Q3 | 3.62 Million USD | 5.8% |
| 2003 Q2 | 3.42 Million USD | -4.46% |
| 2003 Q4 | 3.87 Million USD | 6.8% |
| 2002 Q1 | 3.45 Million USD | -0.16% |
| 2002 Q3 | 3.79 Million USD | 1.28% |
| 2002 Q4 | 3.4 Million USD | -10.11% |
| 2002 Q2 | 3.74 Million USD | 8.32% |
| 2002 FY | 3.4 Million USD | -1.54% |
| 2001 Q3 | 2.22 Million USD | 51.28% |
| 2001 Q1 | 1.43 Million USD | 20.66% |
| 2001 FY | 3.46 Million USD | 190.71% |
| 2001 Q4 | 3.46 Million USD | 55.78% |
| 2001 Q2 | 1.46 Million USD | 2.23% |
| 2000 Q3 | 1.09 Million USD | 38.7% |
| 2000 FY | 1.19 Million USD | 32.3% |
| 2000 Q1 | 727.39 Thousand USD | -19.18% |
| 2000 Q2 | 792.38 Thousand USD | 8.93% |
| 2000 Q4 | 1.19 Million USD | 8.34% |
| 1999 Q4 | 900 Thousand USD | 50.0% |
| 1999 Q2 | 600 Thousand USD | -14.29% |
| 1999 FY | 900 Thousand USD | 28.57% |
| 1999 Q1 | 700 Thousand USD | 0.0% |
| 1999 Q3 | 600 Thousand USD | 0.0% |
| 1998 Q2 | 600 Thousand USD | 20.0% |
| 1998 Q3 | 500 Thousand USD | -16.67% |
| 1998 Q4 | 700 Thousand USD | 40.0% |
| 1998 FY | 700 Thousand USD | -58.82% |
| 1998 Q1 | 500 Thousand USD | -70.59% |
| 1997 Q3 | 1.5 Million USD | 0.0% |
| 1997 FY | 1.7 Million USD | 0.0% |
| 1997 Q4 | 1.7 Million USD | 13.33% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 96.742% |
| Embecta Corp. | 2.03 Billion USD | 98.483% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 93.453% |
| Dynavax Technologies Corporation | 375.02 Million USD | 91.765% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 95.327% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 95.615% |
| PainReform Ltd. | 2.69 Million USD | -1047.603% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 81.159% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -402.997% |
| SCYNEXIS, Inc. | 55.45 Million USD | 44.307% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -235.798% |
| Cosmos Health Inc. | 30.25 Million USD | -2.081% |
| Journey Medical Corporation | 56.49 Million USD | 45.341% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -402.997% |
| Safety Shot Inc | 3.89 Million USD | -693.465% |
| Alpha Teknova, Inc. | 38.55 Million USD | 19.893% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 77.437% |
| Bright Green Corporation | 6.43 Million USD | -379.676% |
| Procaps Group, S.A. | 462.06 Million USD | 93.317% |
| Theratechnologies Inc. | 98.63 Million USD | 68.692% |
| Harrow Health, Inc. | 241.75 Million USD | 87.226% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -252.695% |
| Biofrontera Inc. | 23.13 Million USD | -33.463% |
| DURECT Corporation | 30.4 Million USD | -1.565% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 93.665% |
| Cronos Group Inc. | 43.73 Million USD | 29.39% |
| OptiNose, Inc. | 194.33 Million USD | 84.109% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 96.222% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 36.253% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -47.21% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 82.972% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -718.688% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 41.195% |
| Radius Health, Inc. | 804.29 Million USD | 96.16% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -124.526% |
| ProPhase Labs, Inc. | 42.54 Million USD | 27.412% |
| Phibro Animal Health Corporation | 725.54 Million USD | 95.744% |
| Procaps Group S.A. | 462.06 Million USD | 93.317% |
| Alvotech | 1.88 Billion USD | 98.36% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -120.24% |
| Viatris Inc. | 27.21 Billion USD | 99.887% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 65.831% |
| SIGA Technologies, Inc. | 57.97 Million USD | 46.734% |
| Tilray Brands, Inc. | 892.11 Million USD | 96.538% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 85.95% |
| Shineco, Inc. | 47.6 Million USD | 35.124% |
| PetIQ, Inc. | 645.22 Million USD | 95.214% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -13968.479% |
| Incannex Healthcare Limited | 5.83 Million USD | -429.708% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.971% |
| Alimera Sciences, Inc. | 107.35 Million USD | 71.233% |
| Silver Spike Investment Corp. | 3 Million USD | -926.038% |
| Assertio Holdings, Inc. | 148.41 Million USD | 79.192% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1528.828% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -44.879% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -339.539% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -263.723% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 82.189% |
| Hempacco Co., Inc. | 18.82 Million USD | -64.07% |
| Talphera, Inc. | 6.29 Million USD | -390.97% |
| Alvotech | 1.88 Billion USD | 98.36% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 82.108% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 96.303% |
| Currenc Group, Inc. | 177.67 Million USD | 82.619% |
| Kamada Ltd. | 109.96 Million USD | 71.917% |
| Indivior PLC | 1.95 Billion USD | 98.417% |
| Evoke Pharma, Inc. | 9.64 Million USD | -220.084% |
| Flora Growth Corp. | 17.22 Million USD | -79.317% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -263.723% |
| Evolus, Inc. | 209.68 Million USD | 85.272% |
| HUTCHMED (China) Limited | 536.38 Million USD | 94.243% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 96.465% |
| Akanda Corp. | 12.66 Million USD | -143.763% |